Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of Sao Paulo, Brazil

Imagem de Miniatura
Arquivos
art_SANTOS_Prevalence_and_Pattern_of_Resistance_in_NS5ANS5B_in_2021.PDF (410.94 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
DOVE MEDICAL PRESS LTD
Autores
SILVA, Vanessa Cristina Martins
LEMOS, Marcilio Figueiredo
SANTANA, Rubia Anita Ferraz
DASTOLI, Gregorio Tadeu Fernando
CASTRO, Vanessa Fusco Duarte de
MOREIRA, Regina Celia
Citação
INFECTION AND DRUG RESISTANCE, v.14, p.723-730, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: Globally, it is estimated that 71 million people are chronically infected with hepatitis C, and 10-20% of these will develop cirrhosis and hepatocellular carcinoma. The development of new direct-acting antiviral (DAA) drugs has contributed to sustained virological response (SVR), eliminating the infection and achieving cure of chronic hepatitis C. However, treated patients can develop HCV resistance to DAAs, which can contribute to the failure of treatment. Here, we aimed to evaluate the prevalence and specific pattern of NS5A and NS5B resistance-associated substitutions (RAS) in samples from patients chronically infected with HCV genotype 3a at a public health laboratory, Instituto Adolfo Lutz, Sao Paulo, Brazil. Patients and Methods: Serum samples from the enrolled individuals were submitted to ""in-house"" polymerase chain reaction amplification of NS5A and NS5B non-structural protein genes, which were then sequenced by Sanger method. Results: A total of 170 and 190 samples were amplified and analyzed for NS5A and NS5B, respectively. For NS5A, 20 (12.0%) samples showed some important RAS; 16 (9.0%) showed some type of substitution and 134 (79.0%) showed no polymorphism. No sample showed any RAS for NS5B. Conclusion: This study found important RAS in samples from naive chronic HCV patients in some areas from Sao Paulo. The most prevalent were A62S, A30K, and Y93H, which could indicate an increase in resistance to some DAAs used in HCV treatment.
Palavras-chave
HCV, nonstructural NS5A/NS5B, resistance, polymorphism, RAS
URI
https://observatorio.fm.usp.br/handle/OPI/39874
Referências
  1. Bartolini B, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080212
  2. Chen Q, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104694
  3. Costa VD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216327
  4. Cuypers L, 2016, REV MED VIROL, V26, P408, DOI 10.1002/rmv.1895
  5. European Assoc Study Liver, 2018, J HEPATOL, V69, P461, DOI 10.1016/j.jhep.2018.03.026
  6. Gottwein JM, 2018, GASTROENTEROLOGY, V154, P1435, DOI 10.1053/j.gastro.2017.12.015
  7. Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
  8. Heffernan A, 2019, LANCET, V393, P1319, DOI 10.1016/S0140-6736(18)32277-3
  9. Hernandez D, 2013, J CLIN VIROL, V57, P13, DOI 10.1016/j.jcv.2012.12.020
  10. Hezode C, 2018, J HEPATOL, V68, P895, DOI 10.1016/j.jhep.2017.11.032
  11. Hussaini T, 2016, HEPATIC MED-EVID RES, V8, P61, DOI 10.2147/HMER.S72429
  12. Kalaghatgi P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155869
  13. Kim CW, 2013, CLIN MOL HEPATOL, V19, P17, DOI 10.3350/cmh.2013.19.1.17
  14. Kjellin M, 2019, SCAND J GASTROENTERO, V54, P1042, DOI 10.1080/00365521.2019.1652846
  15. Krishnan P, 2018, ANTIMICROB AGENTS CH, V62, DOI 10.1128/AAC.01249-18
  16. Lawitz EJ, 2016, ANTIMICROB AGENTS CH, V60, P5368, DOI 10.1128/AAC.00763-16
  17. Malta FD, 2010, MEM I OSWALDO CRUZ, V105, P92, DOI 10.1590/S0074-02762010000100014
  18. Ministry of Health (MS), 2013, HLTH MED SERV ANN HL, P26
  19. Ng TI, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02558-16, 10.1128/aac.02558-16]
  20. Pawlotsky JM, 2016, GASTROENTEROLOGY, V151, P70, DOI 10.1053/j.gastro.2016.04.003
  21. Sagnelli E, 2018, INFECTION, V46, P761, DOI 10.1007/s15010-018-1188-3
  22. Sandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3
  23. SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
  24. Sarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011
  25. Scheel TKH, 2013, NAT MED, V19, P837, DOI 10.1038/nm.3248
  26. Sharafi H, 2018, WORLD J HEPATOL, V10, P543, DOI 10.4254/wjh.v10.i9.543
  27. Sorbo MC, 2018, DRUG RESIST UPDATE, V37, P17, DOI 10.1016/j.drup.2018.01.004
  28. Vermehren J, 2012, BEST PRACT RES CL GA, V26, P487, DOI 10.1016/j.bpg.2012.09.011
  29. Wang CF, 2013, ANTIMICROB AGENTS CH, V57, P611, DOI 10.1128/AAC.01874-12
  30. World Health Organization, 2017, GLOBAL HEPATITIS REP

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03